Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies This phase I/II, open-label, multicenter study evaluated pivekimab sunirine (PVEK), a novel CD123 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results